First Trust Advisors
CTKB icon

First Trust Advisors’s Cytek Biosciences CTKB Stock Holding History

First Trust Advisors’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-76,810
Closed -$426K – 2575
2024
Q3 		$426K Buy
76,810
+16,646
+28% +$94.4K ﹤0.01% 2205
2024
Q2 		$336K Sell
60,164
-184,125
-75% -$1.11M ﹤0.01% 2189
2024
Q1 		$1.64M Buy
+244,289
New +$1.93M ﹤0.01% 1816
2023
Q2 		– Sell
-31,226
Closed -$287K – 2367
2023
Q1 		$287K Sell
31,226
-175,841
-85% -$1.89M ﹤0.01% 2247
2022
Q4 		$2.11M Buy
+207,067
New +$2.78M ﹤0.01% 1674

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

First Trust Advisors's CTKB Position: Q4 2024 in Review

First Trust Advisors sold out of Cytek Biosciences (CTKB) in Q4 2024, closing a stake of 76,810 shares — an estimated $426K sold.

First Trust Advisors first reported a position in CTKB in Q4 2022 and held it in 5 quarters. The position peaked at $2.11M in Q4 2022. 152 funds tracked by Wall St. Rank hold CTKB as of Q4 2024.

  • First Trust Advisors reported no remaining Cytek Biosciences position as of Q4 2024 after selling out during the quarter.
  • First Trust Advisors sold 76,810 Cytek Biosciences shares in Q4 2024, an estimated $426K.
  • First Trust Advisors first reported a position in Cytek Biosciences in Q4 2022 and held it in 5 quarters.
  • First Trust Advisors's Cytek Biosciences position peaked at $2.11M in Q4 2022.
  • 152 funds tracked by Wall St. Rank held Cytek Biosciences as of Q4 2024.

Based on First Trust Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.